Shares of Sana Biotechnology Inc. (SANA) were up over 300% at $7.50 in after-hours trading on Tuesday, following positive initial results from an investigator-sponsored, first-in-human study of UP421 in type 1 diabetes.
UP421 is an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology. The study, conducted in partnership with Uppsala University Hospital, tests the hypothesis of whether HIP-engineered insulin-producing pancreatic cells can be transplanted safely and help to regain insulin production in individuals with type 1 diabetes without the need for simultaneous treatment with immunosuppressive medicines.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.